Loading…
Estrella Immunopharma, Inc. is projected to rise to $0.9334 by 2027, a +1% move from its current price of $0.9269. ESLA is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $0.8907 | $0.9262 | $0.9631 | -0.08% |
| Jul 14 | $0.8757 | $0.9255 | $0.9781 | -0.15% |
| Jul 15 | $0.8642 | $0.9248 | $0.9896 | -0.23% |
| Jul 16 | $0.8546 | $0.9241 | $0.9993 | -0.30% |
| Jul 17 | $0.8461 | $0.9234 | $1.01 | -0.38% |
| Jul 18 | $0.8384 | $0.9227 | $1.02 | -0.45% |
| Jul 19 | $0.8314 | $0.922 | $1.02 | -0.53% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.8314 | $0.922 | $1.02 | -0.53% |
| Week 2 | $0.7923 | $0.9171 | $1.06 | -1.05% |
| Week 3 | $0.7626 | $0.9123 | $1.09 | -1.58% |
| Week 4 | $0.7379 | $0.9075 | $1.12 | -2.10% |
| Week 5 | $0.7162 | $0.9027 | $1.14 | -2.61% |
| Week 6 | $0.6969 | $0.8979 | $1.16 | -3.13% |
| Week 7 | $0.6793 | $0.8932 | $1.17 | -3.64% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Estrella Immunopharma, Inc. is a clinical-stage biopharmaceutical company that develops T-cell therapies for blood cancers and solid tumors in the United States. Its lead candidate EB103 is in Phase I/II for diffuse large B-cell lymphoma.
EB104 is in pre-clinical trial for diffuse large B-cell lymphoma and acute lymphocytic leukemia, and EB201 is in pre-clinical trial for systemic lupus erythematosus. It offers ARTEMIS, a cell receptor platform to develop and commercialize T-cell therapies targeting CD19 and CD22 for hematologic malignancies. It has a collaborative agreement with Eureka and Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103.
Estrella Immunopharma, Inc. was founded in 2006 and is headquartered in EmeryVille, California. Estrella Immunopharma, Inc. is a subsidiary of Eureka Therapeutics, Inc.
Estrella Immunopharma, Inc. trades as ESLA in the healthcare sector. The current price is $0.91 and the market cap is $39.16M, with a rank of 4680. The stock’s pipeline includes EB103 in Phase I/II for diffuse large B-cell lymphoma, EB104 in pre-clinical trials, and EB201 in pre-clinical development under the ARTEMIS platform for CD19 and CD22 targeted T-cell therapies.
The long-range forecast projects upside, with 2030 average price of $1.25, 2040 average price of $2.32, and 2050 average price of $3.80, accompanied by ROIs of 37.7, 154.6, and 317.4 respectively and bullish sentiment, while near term remains neutral. The 30-day technical picture supports a range in the near term, with volatility noted in the data.
A major floor 19.9% below — a decisive break under it would weaken the trend.
Price is testing support right now (2.9% away) — a key level to hold.
The nearest ceiling, 24.1% above — a clean break opens room to run.
A major ceiling 107.1% above — clearing it would confirm fresh momentum.
Key ESLA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ESLA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.9414 | Sell | $0.9415 | Sell |
| MA 10 | $0.9726 | Sell | $0.9601 | Sell |
| MA 20 | $0.986 | Sell | $0.9963 | Sell |
| MA 50 | $1.13 | Sell | $1.11 | Sell |
| MA 100 | $1.23 | Sell | $1.20 | Sell |
| MA 200 | $1.43 | Sell | $1.27 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 39.96 | Neutral |
| Stoch RSI (14) | 60.51 | Neutral |
| CCI (20) | -99.33 | Neutral |
| Williams %R (14) | -80.71 | Info |
| MACD (12,26,9) | 0.00 | Buy |
| ROC (12) | -7.30 | Sell |
| Bollinger %B (20,2) | 0.19 | Neutral |
| Stochastic %K (14) | 19.29 | Buy |
| TRIX (15) | -0.76 | Sell |
| Awesome (5,34) | -0.10 | Sell |
| Ultimate (7,14,28) | 36.97 | Neutral |
| Momentum (10) | -0.02 | Sell |
| Aroon Osc (25) | -76.00 | Sell |
| Hull MA (9) | 0.90 | Buy |
| ADX (14) | 21.86 | Sell |
| ATR (14) | 0.04 | Info |
The 30-day technical picture is NEUTRAL. RSI14 is 40 and the stock trades near its near-term levels. The SMA50 is $1.17 and the SMA200 is $1.43, signaling a draw between short- and longer-term momentum.
Support sits at $0.91 and resistance at $1.16, with a 30-day price range from $0.6951 to $1.19. The stock carries an annualized volatility of 80% indicating substantial price movement potential.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.90 | $0.9269 | $1.18 | 0% | Neutral | |
| $0.7132 | $0.9334 | $1.31 | +1% | Neutral | |
| $0.749 | $1.02 | $1.51 | +10% | Neutral | |
| $0.678 | $0.9584 | $1.47 | +3% | Neutral | |
| $0.8804 | $1.28 | $2.03 | +39% | Bullish | |
| $1.05 | $1.58 | $2.58 | +71% | Bullish | |
| $0.9642 | $1.49 | $2.48 | +61% | Bullish | |
| $0.9767 | $1.55 | $2.64 | +67% | Bullish | |
| $0.9535 | $1.55 | $2.69 | +67% | Bullish | |
| $0.9176 | $1.53 | $2.70 | +65% | Bullish | |
| $1.30 | $2.41 | $4.63 | +160% | Bullish | |
| $1.79 | $3.98 | $8.55 | +330% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $0.90 | $0.9269 | $1.13 | +0.00% |
| August 2026 | $0.7582 | $0.9057 | $1.12 | -2.29% |
| September 2026 | $0.717 | $0.8651 | $1.09 | -4.48% |
| October 2026 | $0.733 | $0.8922 | $1.13 | +3.13% |
| November 2026 | $0.7533 | $0.9238 | $1.19 | +3.54% |
| December 2026 | $0.737 | $0.91 | $1.18 | -1.49% |
Click any year to see its month-by-month ESLA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, ESLA is projected to trade between $0.90 and $1.18, averaging $0.9269 — a potential gain of 0% from today's $0.9269. Price action looks broadly range-bound.
Estrella Immunopharma, Inc.'s 2027 outlook centres on $0.9334, within a $0.7132 to $1.31 range. That is up +1% on the projected 2026 average. That marks a +1% change versus current levels. A consolidation phase looks the most probable path here.
By 2028, ESLA could reach as high as $1.51, with a base case around $1.02 and support toward $0.749 — roughly +10% from $0.9269. Price action looks broadly range-bound.
Expect ESLA to range from $0.678 to $1.47 through 2029. The $0.9584 average target implies a +3% move from current prices. That is -6% versus the projected 2028 average. A consolidation phase looks the most probable path here.
The ESLA price prediction for 2030 points to an average of $1.28 (low $0.8804, high $2.03) — a potential gain of +39% on today's $0.9269. Momentum favours further upside here.
In 2031, ESLA is projected to trade between $1.05 and $2.58, averaging $1.58 — a potential gain of +71% from today's $0.9269. That is up +23% on the projected 2030 average. Buyers look set to stay in control over this stretch.
Estrella Immunopharma, Inc.'s 2032 outlook centres on $1.49, within a $0.9642 to $2.48 range. That is -6% versus the projected 2031 average. That marks a +61% change versus current levels. Momentum favours further upside here.
By 2033, ESLA could reach as high as $2.64, with a base case around $1.55 and support toward $0.9767 — roughly +67% from $0.9269. Buyers look set to stay in control over this stretch.
Expect ESLA to range from $0.9535 to $2.69 through 2034. The $1.55 average target implies a +67% move from current prices. That is up 0% on the projected 2033 average. Momentum favours further upside here.
The ESLA price prediction for 2035 points to an average of $1.53 (low $0.9176, high $2.70) — a potential gain of +65% on today's $0.9269. Buyers look set to stay in control over this stretch.
In 2040, ESLA is projected to trade between $1.30 and $4.63, averaging $2.41 — a potential gain of +160% from today's $0.9269. That is up +58% on the projected 2035 average. Momentum favours further upside here.
Estrella Immunopharma, Inc.'s 2050 outlook centres on $3.98, within a $1.79 to $8.55 range. That is up +65% on the projected 2040 average. That marks a +330% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in ESLA today (≈ 1,078.865034 ESLA) could be worth
$4,296.32
+$3,296.32 (+330%) by 2050 · US Dollar
Based on the average projected ESLA price of $3.98 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ESLAwould be worth at today's price.
$1,000 invested in ESLA on Jul 10, 2025 (≈ 1,082.251053 ESLA) would be worth
$1,003.14
+$3.14 (+0.3%) today · 1.00× · US Dollar
Based on a ESLA entry price of $0.924 vs. today's $0.9269.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.983 | $942.93 | -5.7% |
| 1 month ago | $1.06 | $874.43 | -12.6% |
| 3 months ago | $1.84 | $503.75 | -49.6% |
| 6 months ago | $1.06 | $874.43 | -12.6% |
| 1 year ago | $0.924 | $1,003.14 | +0.3% |
| All time (4.8y) ago | $9.75 | $95.07 | -90.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ESLA forecast.
Our base-case forecast reaches $1.90 around 2040.
Implied market cap at $1.90: $81.77M
2030 shows an average price of $1.25 with a min of $0.8486 and a max of $2.01, and a ROI of 37.7, with bullish sentiment. The forecast for 2040 shows an average of $2.32 (min $1.21, max $4.52) and a ROI of 154.6, with bullish sentiment. The 2050 projection indicates an average of $3.80 (min $1.71, max $8.32) and a ROI of 317.4, still with bullish sentiment.
These figures illustrate upside potential over the longer horizon, while recognizing that these are estimates and not guarantees. The path from 2030 to 2050 suggests meaningful appreciation relative to the current price, albeit with inherent uncertainty and market risk.
Tap a question to reveal the answer.
2030 avg $1.25, min $0.8486, max $2.01; ROI 37.7; sentiment BULLISH.
Forecast shows neutral in 2026–2029, then bullish from 2030 onward, with 2031 ROI 70.1 and long-term ROIs of 154.6 (2040) and 317.4 (2050). These are estimates, not guarantees.
2050 max is $8.32 and average is $3.80, so a $5 level is within the forecast range, but not guaranteed.
Current price is $0.91; market cap is $39.16M; rank is 4680.
RSI14 is 40; SMA50 is $1.17; SMA200 is $1.43; support at $0.91; resistance at $1.16. The 30-day range is $0.6951 to $1.19 and annualized volatility is 80%.
Estrella Immunopharma, Inc. Community Discussion
0Share your Estrella Immunopharma, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.